·
·
jan nolta Apr 24
Mesoblast cell therapy shows significant benefit in #COVID19patients - small trial, but promising results. #coronavirus#celltherapy#MSC#mesenchymal....................
Scott Olson Cell Therapy Lab
·
Apr 26
Replying to
@jan_nolta
It'll probably work. I hope there's (a) discrete mechanism(s) that can be pinpointed to keep the usage on track to keep signal well above noise...............................................
Description
Jan A. Nolta is an American scientist and the director of the stem cell program at the UC Davis School of Medicine and Institute for Regenerative Cures. She is Scientific Director for the UC Davis Good Manufacturing Practice and editor of the journal stem cells ......... ....................................................................... The names below are The Team Overseeing COVID 19 MSCs trials Currently in Progress To ensure Comprehensive procedures and accurate reporting is carried out ........................................ Journal Pre-proof
Cell-Based Therapies for COVID-19: Proper Clinical Investigations are Essential.
Maroun Khoury , Patricia R.M. Rocco , Donald G Phinney , Mauro Krampera , Ivan Martin , Sowmya Viswanathan , Jan A. Nolta , Katarina LeBlanc , Jacques Galipeau , Daniel J. Weiss
Cell Therapy News/Articles, page-3819
-
- There are more pages in this discussion • 14,006 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $21.32M | 17.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5460 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 978 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |